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O B J E C T I V E S The aim of this prospective study was to identify the most effective and safest
regimen among different thrombolytic treatment strategies.
B A C KG ROUND The best treatment strategies for prosthetic valve thrombosis have been controversial.
METHOD S Transesophageal echocardiography–guided thrombolytic treatment was administered
to 182 consecutive patients with prosthetic valve thrombosis in 220 different episodes (156 women;
mean age, 43.2  13.06 years) between 1993 and 2009 at a single center. These regimens
chronologically included rapid (Group I), slow (Group II) streptokinase, high-dose (100 mg) tissue
plasminogen activator (t-PA) (Group III), a half-dose (50 mg) and slow infusion (6 h) of t-PA without bolus
(Group IV), and a low dose (25 mg) and slow infusion (6 h) of t-PA without bolus (Group V). The
endpoints were thrombolytic success, in-hospital mortality, and nonfatal complication rates.
R E S U L T S The overall success rate in the whole series was 83.2%; it did not differ signiﬁcantly among
Groups I through V (68.8%, 85.4%, 75%, 81.5%, and 85.5%, respectively; p  0.46). The overall complication
rate in the whole series was 18.6%. Although the overall complication rate was similar among Groups I
through IV (37.5%, 24.4 %, 33.3%, and 29.6%, respectively; p 0.05 for each comparison), it was signiﬁcantly
lower in Group V (10.5%, p  0.05 for each). The combined rates of mortality and nonfatal major
complications were also lower in Group V than in the other groups, with all differences signiﬁcant except for
comparison of Groups IV and V. By multivariate analysis, the predictors of combined mortality plus nonfatal
major complications were any thrombolytic therapy regimen other than Group V (odds ratios for Groups I
through IV: 8.2, 3.8, 8.1, and 4.1, respectively; p  0.05 for each) and a history of stroke/transient ischemic
attack (odds ratio: 3.5, p  0.011). In addition, there was no mortality in Group V.
CONC L U S I O N S Low-dose slow infusion of t-PA repeated as needed without a bolus provides effective
and safe thrombolysis in patients with prosthetic valve thrombosis. (Comparison of Different TRansesophageal
Echocardiography Guided thrOmbolytic Regimens for prosthetIc vAlve Thrombosis; NCT01451320) (J Am Coll
Cardiol Img 2013;6:206–16) © 2013 by the American College of Cardiology Foundation
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207rosthetic valve thrombosis (PVT) is a serious
complication with high mortality and mor-
bidity (1). The PVT incidence was reported to
be 0.03% in bioprosthetic valves (2), 0.5% to 8%
n mechanical valves in the mitral and aortic posi-
ions, and as high as 20% in mechanical tricuspid
alves (3). The best treatment of PVT is controver-
ial, although surgery (4–8), anticoagulation (4,9),
nd thrombolysis (9–22) options have been available.
See page 217
In the most recent American College of Cardiolo-
gy/American Heart Association guidelines (23),
surgery is recommended for patients in New York
Heart Association (NYHA) functional classes III
and IV unless surgery is high risk (functional class
IIA). Thrombolysis is given a NYHA functional
class IIA indication in patients with right-sided
valve thrombosis and a NYHA functional class IIB
indication in patients with a left-sided but small
thrombus. The European Society of Cardiology
guidelines (24) also emphasize surgery for critically
ill patients (NYHA functional class IC) and restrict
thrombolysis to patients with high surgical risk
and/or right-sided valve thrombosis. Moreover, the
use of fibrinolytic therapy with a nonobstructive
thrombus was also discouraged because of the
increased risk of bleeding and embolization. On the
other hand, the Society for Heart Valve Disease
(25) clearly states that thrombolysis is the first-line
treatment for obstructive PVT, independent of
NYHA functional class and thrombus size. The
American College of Chest Physicians guidelines
recommend thrombolysis for small thrombi and
surgery for larger ones (26). Ca´ceres-Lo´riga et al.
(11), Lengyel et al. (9), Shapira et al. (12), and
Alpert (13) emphasized the role of thrombolysis.
Despite the improvement in mortality within the
past decade, surgical management of PVT has been
associated with a significant death risk for 40 years.
Therefore, establishment of a more effective strat-
egy to treat PVT is crucial, especially in the devel-
oping countries where this condition is prevalent.
Currently, there is no agreement on the type, dose,
and route of administration of thrombolytic agents.
In this study, thrombolysis was used as first-line
therapy, and we prospectively analyzed our 16-year
experience in which 5 different thrombolytic regi-
mens were used for the treatment of PVT in
chronological order, in an effort to identify the most
effective and safest regimen.M E T H O D S
Rationale of the study methods. This single-center
study was not a randomized, controlled study com-
paring thrombolytic therapy (TT) with surgery for
the treatment of PVT. The sporadic and cata-
strophic nature of PVT historically has not allowed
a large-scale, randomized, controlled clinical trial to
be conducted on this entity. Because previous re-
ports demonstrated that surgery was associated with
high mortality (average 20%) and this finding was
similar to our institution’s surgery outcomes for the
treatment of PVT between 1996 and 2005 (8), we
did not intend to randomize patients to a cardiac
surgery group; therefore, such a comparison was not
performed. TT and surgery were not considered as
alternative treatment options; instead,
they were considered as complementary
treatments. Hence, TT was the first treat-
ment option for virtually all patients with
PVT at our institution, and since the first
patient was enrolled in this study, surgery
was only performed in the patients who
had a major contraindication to TT or in
those in whom thrombolysis failed. De-
spite the improvements in anesthesia and
perioperative care, in-hospital mortality of
surgery for the treatment of obstructive
PVT was 17% at our institution (between
2006 and 2011, 64 patients with PVT who
had a contraindication to TT or in whom
TT failed underwent surgery; 11 of these
patients died after the surgery) and 11% in
a recent study from Belgium (27). These
findings necessitate a nonsurgical therapy;
in particular, thrombolysis with new TT
protocols for the treatment of PVT.
The rationale for the different TT regimens and,
in particular, the reasons for switching from one to
another were as follows. Throughout this study, we
constantly evaluated the outcomes of the patients
after each course of TT. When a particular regimen
was applied to 4 patients, an official data evaluation
meeting was held by the physicians involved in the
care of these patients. The TT regimen was con-
tinued for the next 4 patients if the complication
rate was favorable compared with the previous
regimen. The TT regimen was discontinued and a
new regimen was started when it resulted in a
complication rate similar to that of the previous
regimen. Our first TT protocol (Group I) was
stopped because the major complication rates were
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208use potentially safer regimens by reducing the dose
of TT and/or increasing the infusion duration of
the same dose to achieve a reduced complication
rate in each subsequent group. Therefore, the reg-
imens described were used as the first treatment
option in all patients who presented with PVT in
chronological order. A new thrombolytic protocol
was used in the next therapy period. Finally, the
groups in which the complication rates increased
rapidly during the earlier course of treatment re-
tained a relatively small number of patients due to
termination of that protocol.
We hypothesized that the most serious compli-
cation of TT (bleeding) could be diagnosed early,
and the TT infusion could be stopped immediately
with a low-dose, slow-infusion protocol.
Similarly, we did not use concomitant heparin
anticoagulation with TT due to the potential in-
creased risk of bleeding.
Patient population and enrollment. The study was
approved by the local ethics board, and the patients
were enrolled after providing informed consent. A
total of 182 consecutive in-hospital patients with
220 episodes of mechanical PVT between 1993 and
2009 were included in the study. A PVT episode
refers to the entire treatment period of a patient
who is admitted to the hospital with a PVT and
includes all TT infusions per thrombolytic regimen
whether or not each infusion was successful. If the
same patient was readmitted at a different time with
rethrombosis of the prosthetic heart valve, this was
considered a separate PVT episode.
The exclusion criteria were as follows: patients
with a contraindication (Table 1) to thrombolytic
treatment, patients with asymptomatic nonobstruc-
tive PVT without a history of recent thromboem-
bolism and with a thrombus diameter of 10 mm,
patients with prosthetic valve obstruction who had no
Table 1. Contraindications of Thrombolytic Therapy
Absolute Contraindication Relative Contraindi
Left atrial thrombus Active peptic ulcer
Recent (3 weeks) ischemic stroke Blood pressure 180/110
Hemorrhagic stroke INR 2–3†
Early (4 days) post-operative period Recent (4 wk) internal b
Traumatic accident 4 weeks Previous SKZ therapy (5 d
Bleeding diathesis‡ Recent CPR
Intracranial mass Infective endocarditis
Active internal bleed Hemorrhagic retinopathy
Aortic dissection Pericarditis
*Patients with hemorrhagic conversion of cerebral infarction on the neuroradio
time that the thrombolytic treatment decision was made. Thrombolytic agents
setting was appropriate to avoid treatment delays. ‡Patients with acquired/con
CPR  cardiopulmonary resuscitation; INR  international normalized ratio; SKZ thrombus/mass/pannus on transesophageal echocardi-
ography (TEE), and normal prosthetic valve leaflet
motion on fluoroscopy considered patient-prosthesis
mismatch, and were excluded from the study.
The inclusion criteria were as follows: all patients
with obstructive PVT, patients with nonobstructive
PVT with recent systemic thromboembolism, pa-
tients with asymptomatic nonobstructive PVT with
a thrombus diameter of at least 10 mm, and PVT
patients with ischemic stroke were included only if
they were stable by neuroradiological assessment
after 3 weeks of anticoagulation (patients without
hemorrhagic conversion and/or severe disability).
The patient demographic characteristics, medical
history, date of the surgery, type and make of the
prosthetic valve, rhythm disorders, aspirin use,
NYHA functional class, primary symptoms, and
international normalization ratio (INR) values at
the time of admission were prospectively entered
into a database.
Echocardiography. The diagnosis of PVT was veri-
ed each time by TEE when a patient was admitted
ith thromboembolism or a persistently low INR
at least 2 measurements) for the preceding consec-
tive 3 months and when transthoracic echocardi-
graphy documented prosthetic valve dysfunction
r thrombus. If these criteria were unmet, we did
ot perform TEE unless there was a suspicion of
VT on transthoracic echocardiography or a clini-
al history of recent thromboembolism. There was
o patient with a shorter duration of low INR in
ur study. The diagnostic criteria used in our study
ere published previously (10). All patients under-
ent transthoracic echocardiography and TEE be-
ore and within an hour after the thrombolysis
essions. The cross-sectional area and the largest
iameter of the thrombus were measured on TEE.
hrombus was visualized in all patients with echo-
on No Contraindication
Isolated left atrial appendage thrombus
Hg Acute (4 h) or previous (3 weeks) ischemic stroke*
INR 2
Late (4 days) post-operative period
to 2 yrs) Pregnancy
al study were not included. †INR levels represent the samples obtained at the
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mm
leed
ays
logic
wer
genstreptokinase.
fi
t
b
t
p
i
c
P
t
p
c
o
s
o
1
2
3
4
5
h
i
i
t
s
l
w
v
t
t
C
O
n
1
2
3
w
o
1
2
w
D
1
2
3
i
a
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 6 , N O . 2 , 2 0 1 3
F E B R U A R Y 2 0 1 3 : 2 0 6 – 1 6
Özkan et al.
Thrombolysis of Prosthetic Valve Thrombosis: TROIA
209cardiography. Patients with prosthetic valve ob-
struction who had no thrombus/mass/pannus on
TEE and normal prosthetic valve leaflet motion on
fluoroscopy were considered a “patient-prosthesis
mismatch.” These patients were excluded from the
study and did not receive TT. Patients with inde-
terminate prosthetic valve mass (i.e., thrombus or
pannus unclear) were included in the study (21
episodes), and they received TT per protocol until
they received the maximal thrombolytic dose.
Thrombolytic therapy. TT was administered as a
rst-line therapy to patients with obstructive
hrombus and those with nonobstructive thrombus
ut a history of recent thromboembolism or a
hrombus diameter of 10 mm. The patients who
resented with ischemic stroke (21 episodes) were
ncluded only if they were stable by neuroradiologi-
al assessment after 3 weeks of anticoagulation. The
VT episodes were divided into 5 groups according
o the TT regimen used. In fact, there was no
redetermined time period for each therapy proto-
ol, and each TT regimen was used in chronological
rder, and simultaneous use of 2 regimens in the
ame period or in the same PVT episode did not
ccur.
. Years 1993 through 1997: 3-h infusion of 1.5
million units of streptokinase (SKZ) (16 pa-
tients, 16 episodes), repeat once 24 h later if
needed (maximum total dose: 3 million units).
. Years 1997 through 2001: 24-h infusion of 1.5
million units of SKZ (41 patients, 41 episodes),
repeat once 24 h later if needed (maximum total
dose 3 million units).
. Years 2001 through 2002: 5-h infusion of 90
mg t-PA after a 10-mg bolus (10 patients, 12
episodes), repeat once 24 h later if needed
(maximum total dose 200 mg).
. Years 2002 through 2005: 6-h infusion of 50
mg t-PA without a bolus (27 patients, 27
episodes), repeat once 24 h later up to 3 times if
needed (maximum total dose 150 mg).
. Years 2005 through 2009: 6-h infusion of 25
mg t-PA without a bolus (108 patients, 124
episodes), repeat once 24 h later up to 6 times if
needed (maximum total dose 150 mg).
Anticoagulation with intravenous unfractionated
eparin was withheld during thrombolytic agent
nfusion. Heparin, 70-U/kg bolus and 1,000-U/h
nfusion with a target activated partial thromboplas-
in time between 1.5 and 2.5 times the control, was
tarted immediately after infusion of the thrombo- aytic agent. If repeat thrombolytic agent infusion
as needed, heparin was withheld until the acti-
ated partial thromboplastin time was 50 s. After
hrombolytic success, warfarin was restarted while
he patient was on intravenous heparin.
riteria for thrombolytic success
bstructive thrombus (in the absence of fatal or
onfatal major complications):
) Doppler documentation of the resolution of
increased gradient and decreased valve area.
) Clinical improvement in symptoms.
) Reduction by 75% in major diameter and/or
area of the thrombus.
Complete success was defined when all 3 criteria
ere met and partial success was defined as 3.
Nonobstructive thrombus (in the absence of fatal
r nonfatal major complications):
. Complete success: 75% reduction in throm-
bus area and/or length.
. Partial success: 50% to 75% reduction in throm-
bus area and/or length.
For this study, partial and complete success rates
ere combined.
efinition of complications
. All-cause in-hospital mortality.
. Nonfatal major complications: ischemic stroke,
intracranial hemorrhage, embolism (coronary or
peripheral), bleeding requiring transfusion.
. Nonfatal minor complications: bleeding with-
out need for transfusion, transient ischemic
attack (TIA).
Statistical analysis. Statistical analyses were per-
formed using SPSS version 15.0 (SPSS Inc., Chi-
cago, Illinois). All analyses were done based on
episodes. Descriptive statistics are reported as
mean, SD, median, minimum and maximum values
for continuous variables, and as frequency with
percentages for the categorical variables. Group
comparisons for continuous variables were tested
using the Mann-Whitney U test because the data
distributions were not normal. Comparisons of
categorical variables were evaluated by the chi-
square test using the Monte-Carlo method. Signif-
icance level was accepted as p  0.05 in all
statistical analyses. The Bonferroni correction was
applied to significance level  for multiple compar-
sons. Appropriate univariate predictors for success
nd complications (covariates: TT groups, age, sex,
trial fibrillation, NYHA functional class, history of
i
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210stroke/TIA, obstruction, thrombus area, and
elapsed time since valve surgery) were entered into
multiple logistic regression analyses. The cutoff
values were estimated by receiver-operating charac-
teristic curve analysis.
R E S U L T S
Baseline characteristics. This series of 220 episodes
n 182 patients included 156 women (70.9%) and
4 men (29.1%). The average age was 43.2  13.1
years (median 44 years; range 17 to 82 years). A
subtherapeutic INR was present on admission in
175 episodes (79.5%). The most common symptom
was dyspnea (72.3%). The prevalence of a poor
functional capacity (NYHA functional class III/IV)
was quite high (41.4%). Patients had atrial fibrilla-
Table 2. Comparison of Baseline Characteristics Among Groups
Group I
(n  16)
Group
(n  41
N % n
Demographic characteristics/
medical history
Sex, female/male 6/10 37.5/62.5 29/12 70.7
Age, yrs 39.2  9.7 41.3  1
ETSVS, months 48.2  60.3 26  2
Hypertension 4 25 8 1
Diabetes mellitus 1 6.3 6 1
Atrial ﬁbrillation 8 50 21 5
NYHA functional class I–II/III–IV 9/7 56.3/43.8 24/17 58.5
Stroke or TIA* 7 43.8 17 4
Aspirin use 3 18.8 10 2
Clinical presentation
Dyspnea/HF 11 68.8 25 6
Stroke 2 12.5 5 1
Loss of valve sound 1 6.3 3
Angina/ACS 1 6.3 2
Limb ischemia 1 6.3 2
Asymptomatic 0 0 4
Thrombosed valve
Mitral 12 75 35 8
Aortic 3 18.7 6 1
Tricuspid 0 0 0
Mitral  aortic 1 6.3 0
Echocardiographic features
OT/NOT 9/7 56.3/43.8 20/21 48.8
Monoleaﬂet/bileaﬂet† 7/8‡ 46.7/53.3 21/19 52.5
Mobile THR 6 42.9 19 5
THR area, cm2 1.17  0.57 1.05  0
Values are mean  SD. *The majority of patients had a TIA (25.9%), and 15% ha
years, the number of monoleaﬂet PVT episodes was relatively low in the
monoleaﬂet/bileaﬂet valve numbers were not compared among groups. ‡Data
ACS  acute coronary syndrome; HF  heart failure; ETSVS  elapsed time sin
number of events); NOT  nonobstructive thrombus; NYHA  New York Heart A
thrombus; TIA  transient ischemic attack.tion in 56.6% of the PVT episodes. There was a
history of a stroke/TIA in 40.9% of the episodes
(stroke in 15% and TIA in 25.9%). The prevalence
of hypertension was 13.6%, 6.4% for diabetes, and
25.7% for previous aspirin use. The most common
valve type was the St. Jude Medical (St. Jude
Medical Inc., St. Paul, Minnesota) bileaflet valve
(80 episodes) with the mitral position being the
most common thrombus site (185 episodes).
There were no differences among the groups in
terms of baseline characteristics including sex, age,
elapsed time since valve surgery, heart rhythm,
functional capacity, history of stroke or TIA, pre-
vious aspirin use, clinical presentation, thrombosed
valve position, and echocardiographic findings on
admission (Table 2).
Group III
(n  12)
Group IV
(n  27)
Group V
(n  124)
p
Valuen % N % n %
.3 8/4 66.7/33.3 19/8 70.4/29.6 94/30 75.8/24.2 0.06
42.2  8.6 42.6  11 44.6  14.4 0.37
39.6  29.4 33.3  44.1 23.6  22 0.05
1 8.3 2 7.4 15 12.1 N/A
0 0 0 0 7 5.6 N/A
6 50 14 51.9 61 49.2 0.97
.5 7/5 58.3/41.7 15/12 55.6/44.4 74/50 59.7/40.3 0.99
5 41.7 10 37 51 41.1 0.99
2 16.7 6 22.2 29 23.4 N/A
8 66.7 20 74.1 95 76.6 0.39
1 8.3 2 7.4 11 8.9 N/A
1 8.3 1 3.7 3 2.4 N/A
1 8.3 2 7.4 6 4.8 N/A
0 0 1 3.7 1 0.8 N/A
1 8.3 1 3.7 8 6.5 N/A
9 75 23 85.2 105 84.7 0.78
1 8.3 2 7.4 9 7.3 N/A
2 16.7 2 7.4 10 8.1 N/A
0 0 0 0 0 0 N/A
.2 6/6 50/50 14/13 51.9/48.1 56/68 45.2/54.8 0.91
.5 1/5 16.7/83.3 2/20 9.1/90.9 9/82 9.9/90.1 N/A†
4 36.4 11 40.7 59 47.6 0.89
1.37  0.5 1.15  0.52 1.12  0.57 0.49
ke. †Due to the reduced number of monoleaﬂet valve replacements in recent
onologically latest treatment groups (Groups IV and V). For this reason,
rding the valve type in 1 episode in Group I were missing.
alve surgery; N/A  not applicable (p value was not calculated due to the low
iation; OT  obstructive thrombus; PVT  prosthetic valve thrombosis; THR II
)
%
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211Echocardiographic results. In mitral and tricuspid
bstructive PVT episodes (n  93), the mean valve
rea was 1.08 0.3 cm2 (median 1.09 cm2; range 0.5 to
1.7 cm2); and the average peak and mean gradients were
9.9 12.4 mm Hg (median 29 mm Hg; range 10 to 70
m Hg) and 16.6 8.6 mm Hg (median 17 mm Hg;
ange 3 to 45 mm Hg), respectively. In aortic obstructive
VT episodes (n 12), the mean valve area was 1.02
.3 cm2 (median 0.98 cm2; range 0.6 to 1.3 cm2),
and the average peak and mean gradients were 83.2 
13.8 mm Hg (median 84 mm Hg; range 70 to 105
mm Hg) and 52.6  8 mm Hg (median 53; range
42 to 65 mm Hg), respectively.
In nonobstructive mitral and tricuspid PVT ep-
isodes (n 106), the mean valve area was 2.4 0.5
cm2 (median 2.4 cm2; range 1.75 to 3.5 cm2), and
he average peak and mean gradients were 14.7  7
m Hg (median 15 mm Hg; range 6 to 40 mm Hg)
nd 6.6  4 mm Hg (median 6 mm Hg; range 2 to
5 mm Hg), respectively. In aortic nonobstructive
VT episodes (n 9), the mean valve area was 2.2
.4 cm2 (median 2.2 cm2; range 1.9 to 2.6 cm2), and
the average peak and mean gradients were 38  10
mm Hg (median 37 mm Hg; range 31 to 55 mm Hg)
and 20.7 4 mm Hg (median 21 mm Hg; range 17
to 27 mm Hg), respectively.
The PVT was obstructive in 105 episodes
(47.7%) and nonobstructive in 115 (52.3%). The
number of obstructive episodes did not differ among
Groups I through V (56.3% vs. 48.8%, 50.0%,
51.9%, and 45.2%, respectively; p  0.91). The
thrombus area could be measured in 185 episodes
(85.5%) and showed no significant difference
among Groups I through V (mean 1.17 cm2 [me-
ian 1.15 cm2]; mean 1.05 cm2 [median 0.95 cm2];
1.37 cm2 [median 1.4 cm2]; 1.15 [median 1.1 cm2];
1.12 cm2 [median 1.0 cm2] cm2, respectively; p 
.49).
Determinants of treatment success. A successful re-
ult was obtained in 83.2% of the episodes. The
uccess rate was not different among Groups I
hrough V (68.8%, 85.4%, 75.0%, 81.5%, and
5.5%, respectively; p 0.46). The average doses of
T agents per PVT episode used were 2.06  0.75
median 1.5) million units SKZ in Group I, 2.12 
.75 (median 1.5) million units SKZ in Group II,
23.33  41.41 (median 100) mg t-PA in Group
II, 66.11  27.19 (median 50) mg t-PA in Group
V, and 55.85  32.53 (median 50) mg t-PA in
roup V. A similar success rate was obtained with
he lowest t-PA dose in Group V.
The success rate did not appear to be affected bybstructive thrombus, poor NYHA functional class,istory of stroke/TIA, atrial fibrillation, the posi-
ion of thrombosed valve, bileaflet or monoleaflet
alve, mobility of thrombus, history of hypertension
r diabetes, suboptimal INR value on admission,
nd previous aspirin use (Table 3). A shorter time
nterval since valve surgery and/or female sex were
ssociated with a higher likelihood of success (21.8 
1.5 months vs. 58.0  49.4 months, p  0.001;
7.2% vs. 73.4%, p  0.01, respectively). By mul-
ivariate analysis, the only independent predictor of
n unsuccessful result was a longer time interval
ince valve surgery (odds ratio [OR]: 1.025; 95%
onfidence interval [CI]: 1.012 to 1.039; p 
.001).
Predictors of complications. Complications occurred
n 41 episodes (18.6%) and included death (n  6,
4.6%) and nonfatal major (n  17, 41.5%) and
inor (n  18, 43.9%) complications. Intracranial
emorrhage occurred in 7 patients (2 died, nonfatal
n 5), gastrointestinal hemorrhage in 3, gum bleed
n 4, nosebleed in 4, hemoptysis in 1, vaginal
emorrhage in 1, ischemic stroke in 7 (4 died, 3
onfatal in 4), TIA in 8, acute myocardial infarction
n 3, and peripheral embolism in 3.
The number of complications, mortality, nonfa-
al major complications, minor complications, and
he combined rate of mortality plus nonfatal major
omplications in each group are reported in Table 4.
he overall complication rate was significantly
ower in Group V (10.5%, p  0.05 for each
omparison) compared with all other groups; it did
ot differ among Groups I through IV (37.5%, 24.4%,
3.3%, and 29.6%, respectively; p  0.05 for each
Table 3. Comparison of Success Rates Among Speciﬁc Subsets*
Success, %
Female/male 87.2/73.4
INR effective/ineffective 77.8/84.6
Hypertension, no/yes 83.2/83.3
Diabetes mellitus, no/yes 82.5/92.9
Atrial ﬁbrillation/sinus rhythm 80.9/85.4
NYHA functional class I–II/III–IV 86/79.1
Stroke/TIA, no/yes 86.1/78.9
Aspirin use, no/yes 82.9/83.2
THR site: mitral/aortic/tricuspid 83.2/85.7/78.6
NOT/OT 87/79
Monoleaﬂet/bileaﬂet 82.5/81.3
Mobile/ﬁxed thrombus 83.5/82.8
Age, yrs, successful/failed cases 43 13.7/43.9  9
THR area, cm2, successful/failed cases 1.11 0.55/1.17 0
ETSVS, months, successful/failed cases 21.8 21.5/58 4
*Plus/minus values are mean  SD.p Value
0.01
0.28
0.98
0.32
0.37
0.18
0.16
0.86
0.86
0.12
0.87
0.90
.2 0.56
.43 0.18
9.4 0.001Abbreviations as in Tables 1 and 2.
(*Only signiﬁcant p values V an
Abbreviations as in Table
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212comparison). This difference was primarily driven
by the absence of mortality in Group V (0%)
compared with Groups I (12.5%) and III (16.7%),
and lower nonfatal major complications in Group V
(4.84%) compared with Groups II (12.12%) and IV
(11.1%). The combined number of deaths and
nonfatal major complications was lower in Group V
compared with other groups and was significant for
all comparisons except for Groups IV and V.
The combined rate of mortality and nonfatal
major complications was higher in patients with
previous stroke/TIA (16.7% vs. 6.2%, p  0.01)
and male sex (18.8% vs. 7.1%, p  0.01). Age, sex,
obstructive thrombus, thrombus cross-sectional
f Complications and Death Among Groups
Compli
Total Death Nonfata
% N % n
6 37.5 2 12.5 2
0 24.4 1 2.4 5
4 33.3 2 16.7 1
8 29.6 1 3.7 3
3 10.5 0 0 6
1 19.2 6 2.8 17
.01 for Group I vs.
roup V, 0.03 for
roup II vs. Group V,
.04 for Group III
s. Group V, 0.03
r Group IV vs.
roup V, NS for
ther comparisons
0.01 for Group I
vs. Group V, 0.01
for Group III vs.
Group V, NS
for other
comparisons
NS for all
compariso
are shown; p  0.05 for all other comparisons. †The p value is 0.08 for Groups I
of Combined Complication Rates Among Speciﬁc Subsets
Combined Complication, % p Value
7.1/18.8 0.01
e 4.4/12 0.14
10.5/10 0.93
10.7/7.1 1.00
rhythm 11.8/9.1 0.51
I–II/III–IV 7.8/14.3 0.12
6.2/16.7 0.01
10/12 0.69
10.3/19 0.23
7.8/13.3 0.18
15/11.2 0.52
9.1/11.3 0.6
uncomplicated cases 44.5  8.9/43.1  13.5 0.51
cated/uncomplicated 1.18  0.4/1.11  0.6 0.25
D.
s 1 and 2.area, atrial fibrillation, poor functional capacity
(NYHA functional class III/IV), prosthetic valve
type or position, mobility of thrombus, and history
of hypertension or diabetes were not significant
predictors of complications (Table 5). By multivar-
iate analysis, the independent predictors of com-
bined mortality plus nonfatal major complications
were any TT regimen other than Group V (ORs for
Groups I through IV: 8.21 [95% CI: 1.80 to 37.43],
3.78 [95% CI: 1.05 to 13.61], 8.12 [95% CI: 1.54 to
42.68], 4.13 [95% CI; 1.00 to 16.99], respectively;
p  0.05 for each) and a history of stroke/TIA
OR: 3.47 [95% CI: 1.32 to 9.11]; p  0.01).
D I S C U S S I O N
The aim of this study was to identify a thrombolytic
regimen that could provide successful and safe PVT
resolution. Systemic embolization and intracranial
hemorrhage have been the Achilles’ heel of the TT
in PVT. In this single-center series, which is the
largest cohort published to date, we developed a
strategy of slow, repeated infusions of low-dose
t-PA based on our previous experience with SKZ
and higher doses of t-PA over the years. We
hypothesized that successive low dose (25 mg) and
slow infusion (6 h) of t-PA would induce throm-
bolysis and limit the risk of hemorrhage and em-
bolization. The results of our study indicate that
although the success rate for thrombolysis was
similar among Groups I through V, the Group V
regimen was superior to the other 4 regimens
because it was associated with reduced complica-
ons
jor Minor Combined
% n % n %
12.5 2 12.5 4 25
12.2 4 9.8 6 14.6
8.3 1 8.3 3 25
11.1 4 14.8 4 14.8
4.8 7 5.6 6 4.8
7.9 18 8.5 23 10.8
NS for all
comparisons
0.02 for Group I vs.
Group V, 0.04 for
Group II vs. Group V,
0.03 for Group III
vs. Group V, NS
for other
comparisons†
d V.Table 4. Prevalence o
Group
cati
l Ma
N
I
II 1
III
IV
V 1
Total 4
p value* 0
G
G
0
v
fo
G
o
nsTable 5. Comparison
Female/male
INR, effective/ineffectiv
Hypertension, no/yes
Diabetes, no/yes
Atrial ﬁbrillation/sinus
NYHA functional class
Stroke/TIA, no/yes
Aspirin use, no/yes
THR site: mitral/aortic
NOT/OT
Monoleaﬂet/bileaﬂet
Mobile/ﬁxed THR
Age, yrs, complicated/
THR area, cm2, compli
cases
Values are % or mean  Stions and mortality (Fig. 1).
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213Thrombolytic success. The overall success rate
85.9%) in our study is well within the range of
revious publications, although there has been no
niformity of treatment regimens or definition of
uccess (10,11,14–18,27,28). Moreover, the success
ates were similar in the 5 groups.
Although the success rate after the initial dose of
thrombolytic agent was lower in Group V, at the
nd of the repeated doses of a thrombolytic agent,
n increased success rate could be achieved without
he cost of increased complications. More than 1
-PA infusion was necessary in 75 episodes and 3
n 21 episodes in Group V. Increasing possibility of
uccess with repeated administration of thrombo-
ytic agents under TEE guidance was noted in our
revious publication (10). In Groups I through IV,
1 TT infusion was performed in 6, 17, 4, and 8
pisodes, respectively.
In the overall series, the only multivariate predic-
or of decreased success was a longer time interval
ince valvular surgery. It was reported that the time
nterval between valve surgery and PVT episode
ad no significant effect on success (16,18). Our
esults, on the other hand, indicate that a longer
ime interval is associated with reduced thrombo-
ytic success, perhaps due to the higher incidence of
annus in this group. Pannus formation may not be
asily differentiated from thrombus but obviously
ill not respond to thrombolytic drugs. The in-
Group I
1993-1997
Group II
1997-2001
Group III
2001-2002
0%
20%
40%
60%
80%
100%
Figure 1. Thrombolytic Success and Complication Rates Among
The line graph showing each of the 5 time periods and the study g
tical axis with 3 lines displayed in 3 colors. A nonsigniﬁcant trend t
bined complications is apparent.reased success rate in women was considered a roincidental finding because multivariate analysis
id not demonstrate sex as an independent predic-
or of success.
Complications. The overall complication rate of
8% in our series is close to previously published
esults (11,16,17,20). The mortality rate of 2.8%
ompares favorably with the 5% to 30% mortality
ates of surgical series (5–8). Although there was no
urgery arm in our study, low-dose, slow-infusion
T seems to be safer than surgery based on the
ortality rates of surgery among similar cases at our
nstitution and the published data. In addition,
onfatal complication rates also favor TT over
urgery. The lowest surgical mortality rate to date
mong these patients was reported by Keuleers et al.
27). Although these authors reported an 11%
eath rate for the surgical treatment of PVT, the
onfatal complications including post-operative in-
ection, sepsis, need for a permanent pacemaker,
nd ventricular septal defect increased the com-
ined (death  nonfatal) complication rate to 33%
n this study. In our study, patients in Group V had
combined (death  major  minor) complication
ate of 10.5%. However, PVT patients who under-
ent surgery usually had severe symptoms, were
emodynamically unstable with obstructive/large
hrombi, and experienced TT failure, which, in
urn, might have contributed to increased mortality
Success
Total
Complication
Combined
Complication
up IV
2-2005
Group V
2005-2009
Study Groups and Years
ps on the horizontal axis and percentage of outcomes on the ver-
rd an increase in success and signiﬁcant decline in total and com-Gro
200
the
rou
owaate.
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214Low-dose, slow t-PA infusion in Group V was
associated with a lower complication rate mainly
due to a lower incidence of mortality and nonfatal
major complications. Moreover, the severity of such
events was less in Group V. For example, intracra-
nial hemorrhage in Group I resulted in severely
disabling neurological deficits, whereas less signifi-
cant residual deficits were noted in Group V. Lower
doses, slower infusions, and the 24-h interval be-
tween repeat TT sessions probably allowed earlier
identification of complications.
Rapid thrombolysis is associated with increased
embolic risk, especially in the presence of large
thrombi. This has been reported by our group
(10,19) and in the multicenter PRO-TEE (Pros-
thetic Valve Thrombolysis–Role of Transesopha-
geal Echocardiography) study (15). In the latter
study, the embolic risk increased when the throm-
bus area was 0.8 cm2. Similarly, we calculated the
cutoff value of the thrombus size that predicted
embolic complications. Thrombi 0.9 cm2 were
associated with increased major and minor embolic
events in our study (sensitivity, 80.0%; specificity,
45.1%; area under the curve, 0.64; p  0.02). In
each group, the embolic event rate in patients with
thrombi 0.9 cm2 was 37.5%, 15.0%, 20.0%, 0.0%,
and 8.2%; respectively (p value: not applicable
secondary to the small number of events). Group IV
was also a slow-infusion regimen like Group V,
which may explain the low rates of embolism in the
2 groups even in patients with large thrombi. This
may be related to more gradual lysis of thrombi in
slow-infusion groups compared with rapid destruc-
tion after rapid administration and/or higher doses
of thrombolytic agents.
In the overall series, the multivariate predictors of
favorable outcomes in terms of combined mortality
plus nonfatal major complications were only the
Group V TT regimen and the absence of a stroke/
TIA history. In other words, atrial fibrillation,
obstructive thrombus, larger thrombus, and poor
functional capacity, the so-called predictors of poor
outcome in TT of PVT, did not seem to predict the
combined endpoint in this large cohort of PVT
patients. Thus, we conclude that TT is safe in PVT
patients, and administration of a lower dose (25 mg) and
prolonged (6 h) infusion of t-PA further increase
the safety, even in more seriously ill patients. This
may call for a change in guideline recommenda-
tions. Critically ill patients with cardiogenic shock
and/or pulmonary edema have extremely high sur-
gical risk and appear to benefit from high-dose
t-PA (21,22). In our series, there were 13 criticallyill patients. Eight (1 with cardiogenic shock, 7 with
pulmonary edema) of 13 patients were in Group V,
6 had a successful outcome (29), and other 2
underwent surgery because of TT failure. One
patient with pulmonary edema in Group I had a
stroke; 2 patients with pulmonary edema in Group
II had successful lyses without complications, but
another patient with pulmonary edema underwent
surgery due to TT failure. One patient with cardi-
ogenic shock in Group III died. It appears that the
low-dose, prolonged infusion regimen may help
these critically ill patients. However, there may be
individual circumstances that preclude prolonged
TT in patients with such advanced comorbidities
and presentations (19).
Study limitations. Although our study was a single-
center, nonrandomized, observational study, it is
still remarkable for its size and the fact that a large
number of patients were treated in consistent fash-
ion at a single center.
The medical treatment strategies other than
thrombolytic agents for the patients with PVT have
not changed in the past 2 decades. Therefore, it is
unlikely that the background treatments for these
patients have altered our outcomes over time. How-
ever, the residual confounding effect due to changes
in general patient care cannot be ruled out.
Our study was still not a head-to-head compar-
ison of TT with surgery for the treatment of PVT.
Furthermore, almost 50% of the patients in any of
the study groups had a nonobstructive PVT. In
general, these are smaller thrombi and usually less
symptomatic and have a better prognosis with
either surgery or TT. Some of the groups in this
study had uneven numbers of patients. The fre-
quencies of complications in Groups II and V more
likely represent the associated TT regimen, whereas
the frequency of complications in Groups I, III, and
IV may be less robust because of the relatively small
number of patients included in these groups. These
limitations are important to keep in mind before
applying our conclusions to the current practice.
C O N C L U S I O N S
In this largest cohort of PVT patients published to
date, slow infusion of 25 mg t-PA without a bolus
appears to be the safest thrombolytic regimen with
lower complication and mortality rates for PVT
with no loss of effectiveness compared with higher
doses or rapid infusions of SKZ or t-PA.
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